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Gerd Otto, MD,8 Vincenzo Mazzaferro, MD,42 Peter Neuhaus, MD,46 and Hans J. Schlitt, MD111Background.We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx)
candidates with hepatocellular carcinoma (HCC). Methods. In a prospective-randomized open-label international trial, 525
LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor–free immunosuppression were randomized
4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor–free immunosuppression (group A:
264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS);
intention-to-treat (ITT) analysis was conducted after 8 years. Overall survival (OS) was a secondary endpoint. Results.
Recurrence-free survival was 64.5% in group A and 70.2% in group B at study end, this difference was not significant
(P = 0.28; hazard ratio [HR], 0.84; 95% confidence interval [95% CI], 0.62; 1.15). In a planned analysis of RFS rates at yearly in-
tervals, group B showed better outcomes 3 years after transplantation (HR, 0.7; 95% CI, 0.48-1.00). Similarly, OS (P = 0.21;
HR, 0.81; 95% CI, 0.58-1.13) was not statistically better in group B at study end, but yearly analyses showed improvement out
to 5 years (HR, 0.7; 95% CI, 0.49-1.00). Interestingly, subgroup (Milan Criteria-based) analyses revealed that low-risk, rather than
high-risk, patients benefitedmost from sirolimus; furthermore, younger recipients (age ≤60) also benefited, as well sirolimusmono-
therapy patients. Serious adverse event numbers were alike in groups A (860) and B (874). Conclusions. Sirolimus in LTx re-
cipients with HCC does not improve long-term RFS beyond 5 years. However, a RFS and OS benefit is evident in the first 3 to
5 years, especially in low-risk patients. This trial provides the first high-level evidence base for selecting immunosuppression in
LTx recipients with HCC.
(Transplantation 2016;100: 116–125)Hepatocellular carcinoma (HCC) is a common malig-nancy causing substantial morbidity and mortality
worldwide that can be treated surgically in only about 30%
of patients.1 In many of those surgical cases, liver transplan-
tation (LTx) is the only potentially curative treatment option,
especially in patients where the tumor size, number, and
spread are limited according to the Milan Criteria,2 or other
defined parameters.3,4 Because the vast majority of these pa-
tients have liver cirrhosis, 2 otherwise terminal diseases are6 www.transplantjournal.compotentially cured by LTx. However, good outcomes in these
patients are diminished by the problem of HCC recurrence
or redevelopment in about 1 of 5 individuals. Indeed, immu-
nosuppression needed to prevent organ rejection has long
been associated with cancer,5 and the most commonly used
conventional immunosuppressive drugs are calcineurin in-
hibitors, which have specific tumor-promoting activities.6,7
In contrast, although also immunosuppressive, mammalian
target of rapamycin (mTOR) inhibitors are an exceptionalTransplantation ■ January 2016 ■ Volume 100 ■ Number 1
© 2015 Wolters Kluwer Geissler et al 117class of immunosuppressants with activities that can inhibit
tumor growth, including antiangiogenic,8 antiproliferative 9,10
and even, ironically, have proimmunogenic 11,12 effects. The
mTOR inhibitors have proven effective in treating selective
types of cancer, including renal cell adenocarcinoma.13,14
Unfortunately, in HCC patients receiving LTx, the low level of
evidence for a positive effect of mTOR inhibitors rests on ret-
rospective data analyses 15-20 and small nonrandomized pilotReceived 7 July 2015. Revision requested 28 July 2015.
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cated clinical sites over an 8-year period.MATERIALS AND METHODS
Patient Selection
The LTx recipients were recruited from 45 transplant
centers in Europe (42), Canada (2), and Australia (1) in a
multicenter, randomized, open-labeled, parallel group trial
(EudraCT: 2005-005362-36; Clinicaltrials.gov: NCT00355862).
SiLVER was approximately an 8-year study, consisting of
roughly a 3-year enrollment period (January 2006 to April
2009) with at least a 5-year follow-up; patients remained in
the study for its entire duration, regardless of when they were
randomized. The first patient was randomized in January
2006 and the last patient, last visit was conducted in March
2014. The study included all patients eligible for LTx, with
the inclusion criteria being 18 years or older, histologically
proven HCC before randomization and signed written in-
formed consent. The main exclusion criteria were the pres-
ence of extrahepatic HCC and non-HCC malignancies
within the past 5 years (excluding successfully treated non-
melanoma skin cancer). Multiple-organ recipients, patients
with a known sirolimus hypersensitivity, hyperlipidemia re-
fractory to management, evidence of infection, platelets less
than 75 000/mm3 and women of child-bearing potential not
willing to take contraception were also exclusion criteria.
Randomization was completed in April 2009.
Randomization
Patients were randomized into 2 groups. Group A was
maintained for the study duration on a center-specific mTOR
inhibitor-free, generally calcineurin inhibitor–based, immu-
nosuppressive protocol. This control group of patients
was compared to a second group (group B) that received
mTOR inhibitor–free immunosuppression for the first 4
to 6 weeks, at which time, sirolimus was incorporated
into the regime (target range, 4-10 ng/mL) either as a mono-
therapy or as a combination therapy with non-mTOR
inhibitor–based drugs. As a safety precaution, the protocol
included a Doppler ultrasound to show hepatic artery pa-
tency before initiating sirolimus. Guidelines were given to
prevent overimmunosuppression in group B in case sirolimus
was used in combination with other immunosuppressants;
a regimen containing no more than 3 immunosuppressive
agents (one being sirolimus) was allowed, and sirolimus
monotherapy was encouraged. Investigators and patients
were not masked to the study treatment. Details of theclinical protocol, including guidelines for immunosuppres-
sion use, have been published previously.22
The enrolled population included patients with HCC tu-
mors that demonstrated liver cirrhosis and were within the
guidelines of the Milan Criteria;2 hereafter referred to as
“low-risk” patients. Additionally, a fraction of recipients
showedmore extensive disease on posttransplant histopatho-
logical assessment. These recipients with tumors outside the
limits of the Milan Criteria were also included into the study
and are referred to as extended criteria or “high-risk” recipi-
ents; patients without liver cirrhosis (regardless of tumor size)
23,24 and patients undergoing salvage LTx were also consid-
ered high risk.25 Minimization method using an interactive
voice response system (IVRS) was applied for treatment
group allocation to obtain minimal imbalance within each
study site and regarding Milan Criteria. In all patients, in-
cluding those receiving pre-LTx anti-tumor therapy (eg,
chemoembolization, radiofrequency ablation) for histologi-
cally proven HCC, Milan Criteria stratification was based
on post-LTx histopathological data. The IVRS randomiza-
tion was performed between day 22 and day 42 after LTx,
allowing for confirmation of HCC in the post-LTx explanta-
tion pathology assessment, when pre-LTx histological confir-
mation was not available.Outcomes
The primary endpoint of RFS was defined as HCC recur-
rence or patient death. Patients underwent a standardized
tumor-specific follow-up at every scheduled visit. These regu-
lar examinations included ultrasound, a chest X-ray, as well
as α-fetoprotein measurements, along with a clinical examina-
tion to detect potentially related symptoms. In case of suspicious
findings, a computed tomography scan/magnetic resonance
imaging/positron emission tomography/bone scintigraphy
was recommended in accordance with existing guidelines; a
biopsy was also recommended to further confirm the HCC
diagnosis. Confirmation of an HCC diagnosis was double-
checked by on-site monitoring. For the purpose of the study,
because of normal delays in establishing a definitive diagnosis
of HCC, the first day of tumor suspicion constituted time of
recurrence. All mentioned timemeasurementswere calculated
based on the day of LTx. In the first year after LTx, patients
were followed up at months 1, 3, 6, 9, and 12; thereafter, pa-
tients had scheduled visits every 6 months until study end.
Main secondary endpoints of the study were: (1) overall
survival (OS), and (2) RFS and OS in the high-risk and
low-risk subgroups. In addition, the incidence of acute rejec-
tion episodes was recorded. All primary and secondary
endpoint data were monitored on-site by the sponsor for
© 2015 Wolters Kluwer Geissler et al 119accuracy by verifying source data and electronic case report
form (eCRF) entries.
Statistical Analysis
Sample size was calculated using the primary endpoint
RFS, assuming proportional hazards and exponential distri-
butions of RFS. TheRFS time distributions of the 2 treatment
groups were compared using a 2-sided (stratified) log-rank
test at a 0.05 significance level. A 5-year RFS rate of 60%
in patients treated with mTOR inhibitor–free immunosup-
pression was expected. An increase to a 5-year RFS rate of
72% due to sirolimus-containing immunosuppression was
assumed. The improvement in the 5-year RFS rate from
60% to 72% corresponds to a hazard ratio (HR) of 0.643.
For detecting an HR of 0.643 with a power of 1 − β = 0.80
in a 3-stage group sequential design (2 interim analyses
followed by 1 final analysis) with an α spending function of
the O'Brien and Fleming type, it was necessary to observe
164 events (HCC recurrences or deaths). Adjusted signifi-
cance levels were α = 0.0002 (after 55 events), α = 0.0120
(109 events), and α = 0.0462 (164 events) for first, second,
and final analyses, respectively. Assuming a planned accrual
time of 2.5 years and a follow-up time of at least 5 years from
the last patient recruited, a total of 405 patients were ex-
pected to yield the necessary number of events. With a lost
to follow-up rate of about 20%, 255 patients per treatment
group were required.
The primary and secondary endpoints were analyzed using
the intention-to-treat (ITT) population. The ITT population
included all patients randomized who provided informed
consent. According to the statistical analysis plan, patients
with major eligibility violations were to be excluded from
the ITT analysis: (1) extrahepatic tumor (N1, N2, or M1)
manifestation in histology, (2) no histologically proven
HCC, and (3) primary malignancy other than HCC or skin
cancer within 5 years prior to LTx.
The RFS was defined as the time interval between the date
of LTx and the date of recurrence or death (as first event).
Kaplan-Meier methods were applied to estimate RFS rates.
Patients alive and recurrence-free at the time of the analysis
were censored for RFS at the time of last patient contact. Pa-
tients whomissed 2 consecutive visits (without priorHCC re-
currence) were considered “lost to follow-up” and were
censored at the last visit before this interruption. A 2-sided
nonstratified log-rank test (primary confirmatory analysis)
was applied to test the RFS time null hypothesis of no differ-
ence between the randomized treatment groups. Kaplan-
Meier methods were used to analyze the secondary endpoint
of OS, as well as for analyses of defined subgroups; similar
methodswere applied for the analysis of primary and second-
ary endpoints at yearly intervals (years 1, 2, 3, and so on). All
endpoint and subgroup analyses were prespecified in the sta-
tistical analysis plan.
Study Oversight and Role of the Funding Source
This studywas an investigator-initiated trial organized and
sponsored by the University Hospital Regensburg. Parts of
the study oversight were contracted through Chiltern Inter-
national (BadHomburg, Germany). An eCRFwas developed
together with Koehler eClinical (Freiburg, Germany), and
they controlled the IVRS. Pfizer (formerly Wyeth) supplied
sirolimus 1- and 2-mg tablets and provided a research grant,but was not involved in the trial design, analysis, interpreta-
tion, or writing of this report. Sirolimus storage, labeling,
and distribution tasks were outsourced to B&C Clinipack
(Wavre, Belgium). An independent data safety monitoring
board (DSMB) was established to assess safety and planned
interim efficacy data. Yearly DSMB meetings were held in
strict confidence among the 4DSMBmembers; only safety is-
sues and a recommendation regarding continuation of the
study were communicated in writing to the sponsor, with
no information relating to efficacy results. To avoid study
bias, access outside the DSMB to the study efficacy data set
was not permitted, until after the final statistical analysis
was initiated (May 2014).RESULTS
A total of 528 patients were documented in the eCRF.
Three patients without informed consent were excluded from
analyses due to consent withdrawal, a request to delete his/
her data, and an accidental randomization. Therefore,
525 patients were randomized into the study (Figure 1):
264 to groupA and 261 to group B. At end of the trial, a total
of 149 (56.4%) patients in group A and 138 (52.9%) pa-
tients in group B remained in the study. A total of
238 patients ended the study prematurely: 115 (43.6%) in
groupA and 123 (47.1%) in group B. Themost common rea-
son for premature withdrawal was patient death: 82 (31.1%)
in group A and 64 (24.5%) in group B. A total of 93 patients
(33 in group A and 60 in group B) withdrew from the study
for reasons other than death.
From the 525 randomized patients a total of 17 patients
were excluded from the ITT population according to preset
criteria in the statistical analysis plan due to violations of ma-
jor eligibility criteria: 10 patients (1.9%) without histologi-
cally proven HCC, 5 patients (1.0%) with extrahepatic
tumor manifestation, and 2 patients (0.4%) with primary
malignancy other than HCC or skin cancer; these cases were
evenly distributed between groups A (3.0%) and B (3.4%).
A summary of the demographic data is given in Table 1
for all 525 randomized patients. Notably, most patients were
men (86.1%) and white (95.8%). Approximately 60% of
recipients were 60 years or younger, with a mean age
of 57.7 years. Mean time on the waiting list for LTx was
0.53 years. Overall, the treatment groups were well balanced
with regard to the baseline demographic data. The LTx surgi-
cal procedures used were also balanced between groups A
and B, including the use of cell saver devices (Table S1, SDC,
http://links.lww.com/TP/B206).
Comorbidity status is summarized in Table S2 (SDC,
http://links.lww.com/TP/B206), showing an equal distribu-
tion between the groups. Most frequently reported comor-
bidities were cardiovascular diseases, hypertension, and
diabetes mellitus. The treatment groups were also well bal-
anced regarding the causes of the underlying liver disease, in-
cluding cirrhosis because of HCV infection and alcohol use
(Table S3, SDC, http://links.lww.com/TP/B206).
Pathological HCC specifics are summarized in Table S4
(SDC, http://links.lww.com/TP/B206). A total of 326 patients
(64.2%) were within Milan Criteria, whereas 182 patients
(35.8%) had tumors outside Milan Criteria. For most pa-
tients (64.3%), the number of lesions was 1 or 2, whereas
35.7% of patients had 3 lesions or more. The maximum
FIGURE 1. Patient disposition. * Reported for one patient who did not withdraw prematurely. ** Patients excluded from the ITTanalysis due to
violations of major eligibility criteria, as predefined in the statistical analysis plan.
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and greater than 5 cm for 10.4% of patients, and the most
frequent tumor cell grading was G2 (46.3%). Overall, the
treatment groups were well balanced for HCC specifics.
RegardingHCC treatment before LTx, there was no apprecia-
ble difference in the proportion of patients that received treat-
ment in group A (71.1%) versus group B (72.6%), or in the
frequency distribution of treatment types (eg, transarterial
chemoembolization, radiofrequency ablation) among the 2
groups (Table S5, SDC, http://links.lww.com/TP/B206).
Regarding compliance to the group assignments concern-
ing mTOR inhibitor use, it is notable that 30 (11.4%) pa-
tients in group A received mTOR inhibitors (sirolimus or
everolimus) at some time before HCC recurrence during the
trial, and this was due in most cases to calcineurin inhibitor
toxicity. As a measure of adherence in group B, during the
first 2 years post-LTx, 206 (78.9%) patients were on
sirolimus for 50% or greater of this period. At 3, 4, 5, 6,
and 7 years after LTx, 70.1%, 66.3%, 66.9%, 70.0%, and
68.8% of remaining patients in group B were on sirolimus
treatment, respectively, suggesting that at least 2 of
3 patients consistently remained on study medication during
the course of the trial. The median sirolimus trough levelranged from 5.72 to 6.95 ng/ml for the study duration (Fig-
ure S1, SDC, http://links.lww.com/TP/B206), which is in
line with previous reports.26 Exposure to calcineurin in-
hibitors in groups A and B is shown in Table S6 (SDC,
http://links.lww.com/TP/B206); as expected, calcineurin
inhibitor doses were greater in group A than in group B dur-
ing the study.
Before performance of the final analysis, 2 interim analyses
of RFS were performed as planned on the randomized pa-
tients. The first interim analysis was planned after estimation
of the 55th event from available data. Monitoring of the sites
confirmed that the actual number of RFS events was 67:
42 patients (15.8%) and 25 patients (9.6%) in groups A
and B, respectively. The nonstratified log-rank test did not re-
veal a statistically significant difference in RFS (P = 0.0269 at
a significance level of α = 0.0002 in the first interim analysis).
The second interim analysis was performed after 119 con-
firmed events: 67 patients (25.4%) and 52 patients (19.9%)
in groups A and B, respectively. The nonstratified log-rank
test revealed no significant difference in RFS (P = 0.1493).
In the final analysis of the ITT population, the primary
endpoint of RFS in group A was 64.5% (n = 165 patients)
and 70.2% in group B (n = 177) at study end. No significant
TABLE 1.
Demographic data summary (randomized patients)
Group A (N = 264) Group B (N = 261) Total (N = 525)
Age at time of consent, y
Mean 57.3 58.1 57.7
SD 7.64 6.83 7.26
Median 58.0 58.8 58.5
Q1-Q3 53-63 54-63 53-63
Min to Max 22-72 37-75 22-75
N 264 261 525
Age class
≤60 y 159 (60.2%) 152 (58.2%) 311 (59.2%)
>60 y 105 (39.8%) 109 (41.8%) 214 (40.8%)
N 264 261 525
Sex
Female 45 (17.0%) 28 (10.7%) 73 (13.9%)
Male 219 (83.0%) 233 (89.3%) 452 (86.1%)
N 264 261 525
Race
White 251 (95.1%) 252 (96.6%) 503 (95.8%)
African 3 (1.1%) 3 (1.1%) 6 (1.1%)
Asian 6 (2.3%) 4 (1.5%) 10 (1.9%)
Arabic 2 (0.8%) 2 (0.8%) 4 (0.8%)
Other 2 (0.8%) — 2 (0.4%)
N 264 261 525
Time on waiting list, y
Mean 0.58 0.49 0.53
SD 0.849 0.723 0.789
Median 0.28 0.30 0.29
Q1-Q3 0.1-0.7 0.1-0.6 0.1-0.6
Min to Max 0.0-6.9 0.0-7.3 0.0-7.3
N 260 256 516
N is the denominator for percentages (data not always available for all patients).
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by the nonstratified log-rank test (P = 0.2796). The HR was
0.84 (95% confidence interval [95% CI], 0.62-1.15). A
Kaplan-Meier plot for RFS is provided in Figure 2A (top).
However, within the first years after transplantation, the
RFS curve of group B is above the curve of group A, suggest-
ing a better RFS in group B. A preplanned analysis of RFS
rates over years confirmed what was observed in the
Kaplan-Meier plot. Within the first 3 years after transplanta-
tion, a higher RFS rate was observed after 1 and 3 years (P≤
0.0499) in group B compared to group A, and later on, this
treatment difference was no longer apparent (Figure 2B,
top). Hazard ratios ranged from 0.50 (95% CI, 0.29-0.87)
after 1 year to 0.88 (95% CI, 0.65-1.21) after 6 years
(Figure 2B, top). In general, the anatomical location of the
HCC recurrence did not differ greatly between groups A
and B, although there were proportionally slightly fewer re-
currences found in the thoracic region of group B patients
(Table S7, SDC, http://links.lww.com/TP/B206).
Overall survival was analyzed as a secondary endpoint
using Kaplan-Meier methods. Patients without event were
censored at the last date they were known to be alive. At
study end, the OS rate in the ITT population was 68.4% in
group A and 74.6% in group B (Figure 2A, bottom), which
did not reach statistical significance (P = 0.2096, log-rank
test; HR, 0.81; 95% CI, 0.58-1.13). However, additionalplanned analysis of OS rates over years showed better OS
rates in group B compared with group A at 1, 4, and
5 years (P≤ 0.0479) after LTx, with values bordering on sig-
nificance at 2 and 3 years; this difference was not significant
after 5 years (Figure 2B, bottom). Hazard ratios ranged from
0.47 (95%CI, 0.22-0.99) after 1 year to 0.81 (95%CI, 0.58-
1.13) after 7 or 8 years (Figure 2B, bottom). Interestingly,
prespecified subgroup analyses revealed that patients with-
out prior treatment of lesions demonstrated a significantly
higher death rate in group A (28/74 [37.8%]) versus group
B (14/69 [20.3%], P = 0.0381, log-rank test) over the study
period. Additionally, further prespecified subgroup analyses
showed that younger patients (≤60 years) had a significantly
higher death rate in groupA (44/155 [28.4%]) over the study
duration compared to group B (25/145 [17.2%], P = 0.0386,
log-rank test). Causes of death in groups A and B, including
the younger and older subgroup, are summarized in Table
S8 (SDC, http://links.lww.com/TP/B206). This analysis re-
vealed that group B patients overall were not disproportion-
ately susceptible to cardiovascular or infectious death causes,
or other causes of death; however, consistent with the OS
subgroup analysis, tumor-associated deaths were fewer in
group B patients transplanted at 60 years or younger. A
similar pre-LTx comorbidity distribution overall, and
for the recipients 60 years or younger (Table S9, SDC,
http://links.lww.com/TP/B206), suggests that the decrease
in deaths observed in the younger age group is not due to ran-
domization skewing.
A Kaplan-Meier plot was also generated as prespecified to
look for differences in the ITT population for RFS in low-
versus high-risk (based on Milan Criteria) subgroups. Inter-
estingly, the low-risk group showed substantially better
results in group B compared with group A, but results from
the high-risk patients did not suggest a benefit from sirolimus
treatment (Figure 3A, top). More specifically, RFS rates over
the years showed a significant (P ≤ 0.0383) treatment differ-
ence in low-risk group B patients compared with group A re-
cipients during the first 4 years after LTx (Figure 3B, top); no
statistically significant benefit was observed in group B in
high-risk patients (Figure 3B, top); moreover, after 1 year,
the groups A and BKaplan-Meier curves for the high-risk pa-
tients cross and overlap (Figure 3A, top). Likewise, Kaplan-
Meier curves were plotted for OS (Figure 3A, bottom), and
analysis showed a survival advantage at 2 to 4 years in low-
risk patients (P ≤ 0.0231), but only a slight advantage at
1 year (P≤ 0.0361) in the high-risk group (Figure 3B, bottom).
Finally,when a subgroup analysis of those patientsmainly on
sirolimus monotherapy was performed, high RFS (82.9%) and
OS (85.4%) rates were observed in the monotherapy popula-
tion versus combination therapy patients (68.2% and 72.3%,
respectively). Sirolimus monotherapy was defined by patients
on sirolimus immunosuppression alone at the time of at least
50% of their protocol visits. However, this analysis is restricted
by the fact that only 19.2% of group B patients received
sirolimus monotherapy.
Overall, there were 8013 adverse events (AE), with
512 patients (97.5%) reporting at least 1 AE, 97.3% in group
A and 97.7% in group B (Table 2, top). The frequencies of
high-interest AEs are summarized in Table 2 (bottom). On an
individual patient basis, the percentage of patients reporting re-
latedAEswas higher in group B (86.2%) comparedwith group
A (61.0%) (Table S10, SDC, http://links.lww.com/TP/B206).
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(31.1%) in group A and 64 patients (24.5%) in group B. Ad-
verse events related specifically to immunosuppression in the
treatment group that led to death were reported in 8 patients
(3.0%) in group A and 7 patients (2.7%) in group B. All AEs
were classified by primary system organ class and preferred
term using MedDRA version 16.1. Notably, the DSMB did
not identify specific safety concerns during the course of the
trial.
Finally, 80 patients (30.3%) in group A and 84 patients
(32.2%) in group B reported at least 1 episode of acute rejec-
tion. The mean number of rejection episodes was 1.3 (±0.9)
in group A and 1.5 (±0.8) in group B. Considering only rejec-
tions after randomization, the proportion of patients with at
least one episode was slightly higher in group B (23.4%)
compared with group A (17.0%), but this difference did
not reach statistical significance (P = 0.0710, χ2 test).DISCUSSION
In this long-termprospective clinical trial, broad-based prac-
tical incorporation of sirolimus into an immunosuppressiveFIGURE 2. Efficacy data on ITT population.regime for LTx recipients with HCC improved recurrence-
free and OS in the first 3 to 5 years after transplantation, but
thereafter did not indefinitely improve the usual morbidity
and mortality associated with use of conventional, generally
calcineurin inhibitor–based immunosuppression. Importantly,
recipients at a low risk for tumor recurrence showed the
clearest andmost substantial benefit from sirolimus use during
the early post-LTx period, versus high-risk recipients beyond
MilanCriteria that received little or no benefit whatsoever. Ad-
ditionally, our study shows that delayed sirolimus use accord-
ing to our protocol is safe in this specific indication.
With evidence from basic science research and retrospec-
tive data indicating that the anticancer effects of mTOR inhi-
bition could reduce HCC recurrence in LTx,27 investigations
to date have often examined the use of mTOR inhibitors in
patients with advanced HCC. A number of these small trials
or collections of patients have indicated a possible beneficial
effect with relatively advanced tumors.21,28-30 Indeed, it fol-
lows that mTOR inhibitors might provide a means to offer
LTx to persons with extended criteria HCCs that otherwise
would not be transplanted. However, a clear, and perhaps
unexpected, result from our study is that high-risk recipients
FIGURE 3. Efficacy data on low-versus high risk subgroups (ITT population).
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based immunosuppression. Our findings are consistent with
recent trial results showing that everolimus had no effect on
advanced HCC in non-LTx recipients,31 inferring together
thatmTOR inhibitors alone are not effective deterrents of ad-
vanced HCC. On the contrary, patients with tumors staged
within Milan Criteria in our study did receive a substantial
benefit. Consistent with the observation of sirolimus being
most beneficial for lower risk patients, a predetermined sub-
group analysis showed that younger recipients (≤60 years)
have a greater advantage. From these results, we surmise that
the anticancer properties of sirolimus are most able to slow
down development of relatively “naive” tumors in their early
stages, which is also in line with our finding that patients
without pre-LTx treatment of HCC had discernably better
outcomes, even at study end.
Sirolimus treatment in our study protocol was designed to
reflect the “practical” use of immunosuppression in LTx.
Therefore, sirolimus was allowed to be used alone, or incombination with approved standard immunosuppressants
(eg, calcineurin inhibitors, antimetabolites), because a wide
center-to-center variation is expected in normal practice. In-
deed, our study suggests that the presence of sirolimus, even
when used in combinatory immunosuppressive regimens,
positively influences outcomes for LTx patients with HCC.
The degree of advantage for patients on sirolimus can be
measured if an “area between the curves” analysis32 is per-
formed on our ITT data set. Indeed, a post hoc exploratory
“area between the curves” statistical analysis revealed that
patients in group B (including all patients: high and low risk)
had an average gain of RFS of 6.4 months versus group A pa-
tients; the gain in OS in the sirolimus group was 7.0 months.
Sirolimus monotherapy may also offer a further advantage.
When a planned subgroup analysis of those patients on
sirolimus monotherapy was performed, it did show roughly
13% to 15% higher RFS and OS rates, versus combination
therapy patients, but the low proportion (one fifth) of pa-
tients on sirolimus monotherapy makes it difficult to know
TABLE 2.
Number and distribution of selected relevant AEs (randomized population)
Group A (N = 264) Group B (N = 261) Total
Total patients with at least 1 AE 257 (97.3%) 255 (97.7%) 512 (97.5%)
Total number of AEs 3871 4142 8013
Selected AE or AE category (event number in respective group)
Hyperlipidemia, dyslipidemia, hypertriglyceridemia,
or hypercholesteremia
73 137 210
Renal failure 39 35 74
Renal impairment 35 27 62
Acute renal failure 14 11 25
Chronic renal failure 13 4 17
Renal disorder 4 2 6
Total 105 79 184
Peripheral edema 56 96 152
Diarrhea 72 76 148
Incisional hernia 52 91 143
Hypertension 61 77 138
Hepatitis C 60 57 117
Headache 43 48 91
Leukopenia 44 40 84
Anemia 38 45 83
Mouth ulceration, stomatitis, aphtous stomatitis 22 50 72
Pneumonia 25 37 62
Thrombocytopenia 24 36 60
Depression or depressed mood 15 38 53
Wound healing complications, or dehiscence 16 30 46
Insomnia or other sleeping disorder 27 11 38
Hepatic artery stenosis 6 6 12
Hepatic artery occlusion 3 4 7
Hepatic artery thrombosis 4 2 6
Total 13 12 25
Proteinuria 2 22 24
Acne 4 16 20
Portal vein thrombosis 12 2 14
Pneumonitis 0 2 2
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less, our results are consistent with experimental data 7 and
clinical data,33 suggesting that mTOR inhibitors can provide
an advantage even when used in combination with other im-
munosuppressants. This is a critical observation if mTOR in-
hibitors are to have widespread usefulness from an everyday
practical perspective in LTx recipients with HCC.
Determining the safety of sirolimus use was a trial objec-
tive. To reduce possible reported issues of wound healing
problems 34 and occurrence of hepatic vessel thrombotic
events,35 sirolimus introduction was delayed until 4 to
6weeks after LTx. Althoughwound healing problems did oc-
curmore often in the sirolimus armwith delayed use (Table 2),
there was no safety concern noted by the DSMB; regarding
thrombotic events, there clearly was no increase observed in
group B with this protocol. Besides the expected documented
AEs associated with sirolimus treatment,36 the study group
did not identify any serious safety concerns that should warn
against the use of sirolimus in LTx patients with HCC.
In conclusion, results from this unprecedented trial in
HCC patients undergoing LTx show that although flexibleincorporation of sirolimus into an immunosuppressive regimen
does not improve long-term HCC recurrence free and OS out-
comes after 5 years in patients undergoing LTx, outcomes were
improved in the first few years after transplantation, especially
in patientswith tumor featureswithinMilanCriteria. Although
the outcome advantage is eventually lostwith time, thewindow
of benefit spans up to 5 years and besides thewell-known side
effects of this medication, no contraindicative overall disad-
vantage of sirolimus therapy became apparent over the long
term. This trial provides a foundation for sirolimus-based im-
munosuppressive treatment of LTx patients with HCC.
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